Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
No Thumbnail Available
Identifiers
Date
2021-08-16
Authors
Slamon, D J
Neven, P
Chia, S
Jerusalem, G
De Laurentiis, M
Im, S
Petrakova, K
Valeria Bianchi, G
Martín, M
Nusch, A
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
